Patrick J. Muraca, the founding CEO of Nuclea Biotechnologies Inc., is leaving the company to head another biotech firm that will soon be offered to Nuclea's shareholders. Nuclea's board of directors has appointed Muraca the president of NanoDX, a development stage company in Albany, N.Y. The board has appointed biotechnology industry veteran Don Pogorzelski as Nuclea's new president and CEO.